0001640334-21-000147.txt : 20210120
0001640334-21-000147.hdr.sgml : 20210120
20210120165645
ACCESSION NUMBER: 0001640334-21-000147
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210114
FILED AS OF DATE: 20210120
DATE AS OF CHANGE: 20210120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Liu Lina
CENTRAL INDEX KEY: 0001828515
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-21320
FILM NUMBER: 21539346
MAIL ADDRESS:
STREET 1: MAGNA-LAB, INC.
STREET 2: ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
CITY: XICHENG DISTRICT, BEIJING
STATE: F4
ZIP: 00000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Yubo International Biotech Ltd
CENTRAL INDEX KEY: 0000895464
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 113074326
STATE OF INCORPORATION: NY
FISCAL YEAR END: 0228
BUSINESS ADDRESS:
STREET 1: ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
CITY: BEIJING
STATE: F4
ZIP: 00000
BUSINESS PHONE: 86 (010) 6615-5141
MAIL ADDRESS:
STREET 1: ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
CITY: BEIJING
STATE: F4
ZIP: 00000
FORMER COMPANY:
FORMER CONFORMED NAME: MAGNA LAB INC
DATE OF NAME CHANGE: 19940722
4
1
form4.xml
FORM 4
X0306
4
2021-01-14-05:00
false
0000895464
Yubo International Biotech Ltd
YBGJ
0001828515
Liu Lina
YUBO INTERNATIONAL BIOTECH LIMITED
ROOM 105, BUILDING 5, XISHIKU AVENUE
XICHENG DISTRICT, BEIJING
F4
00000
CHINA
false
true
false
false
CFO, Treasurer and Secretary
Class A Common Stock
2021-01-14-05:00
4
D
false
116697438
0
D
0
D
Class A Common Stock
2021-01-14-05:00
4
P
false
13829400
0
A
13829400
I
By Focus Draw Group
The shares reported herein were surrendered to the issuer and canceled in connection with an exchange transaction by and among Platinum International Biotech Co., Ltd.("Platinum"),Yubo International Biotech (Beijing) Limited, the Reporting Person and certain other stockholders of Platinum. No cash consideration was paid in connection with surrender and cancellation of the shares.
The shares reported herein were acquired in connection with an exchange transaction by and among Platinum International Biotech Co., Ltd. ("Platinum"), Yubo International Biotech (Beijing) Limited, the Reporting Person and certain other stockholders of Platinum. The Issuer issued the shares reported herein to the Reporting Person in exchange for the Reporting Person's equity interest in Platinum. No cash consideration was paid in connection with the exchange transaction.
The shares are held by Focus Draw Group, of which the reporting person is the sole director. The Reporting Person disclaims beneficial ownership of the securities except to the extent of her pecuniary interest therein.
/s/ Lina Liu, CFO, Treasurer and Secretary
2021-01-20-05:00